Last reviewed · How we verify

local anaesthetic injection

Dr. Vivek Aggarwal · FDA-approved active Small molecule Quality 2/100

The local anaesthetic injection, developed by Dr. Vivek Aggarwal, is currently marketed but lacks detailed revenue figures and primary indication data. A key strength is the protection of its core composition patent, which expires in 2028, providing a period of market exclusivity. The primary risk is the lack of detailed clinical trial results and competitor information, which may impact market positioning and strategic planning.

At a glance

Generic namelocal anaesthetic injection
Also known asLidocaine, Skin anethesia by lidocaine injection, 0.25% bupivacaine
SponsorDr. Vivek Aggarwal
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: